ProfileGDS5678 / 1424895_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 42% 42% 55% 50% 38% 38% 39% 42% 42% 41% 42% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9901641
GSM967853U87-EV human glioblastoma xenograft - Control 22.9625442
GSM967854U87-EV human glioblastoma xenograft - Control 32.9658442
GSM967855U87-EV human glioblastoma xenograft - Control 43.3309655
GSM967856U87-EV human glioblastoma xenograft - Control 53.1461250
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9616938
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9405238
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8935939
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9434742
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9495942
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9439441
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9465842
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9586641
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9499841